These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 17329185)

  • 41. Overexpression of c-erbB-2 oncoprotein and associated pathobiological factors in invasive primary breast cancer.
    Ray A; Sharma BK; Kaur S; Sharma S; Sharma JK
    Indian J Exp Biol; 2004 Mar; 42(3):253-8. PubMed ID: 15233293
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells.
    Hua G; Zhu B; Rosa F; Deblon N; Adélaïde J; Kahn-Perlès B; Birnbaum D; Imbert J
    Mol Cancer Res; 2009 Mar; 7(3):402-14. PubMed ID: 19276186
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gene expression profiling of ErbB receptor and ligand-dependent transcription.
    Amin DN; Perkins AS; Stern DF
    Oncogene; 2004 Feb; 23(7):1428-38. PubMed ID: 14973552
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Relationship of oncogene C-erbB2 expression to ER, PR and PS2 in breast cancer and its prognostic significance].
    Yang JQ; Chen L; Xing TY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):334-6, 357. PubMed ID: 15181828
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
    Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
    Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Current aspects of the evaluation of ERBB2 activation in breast cancer. Therapeutic perspectives].
    Tse C; Brault D; Etienne J
    Ann Biol Clin (Paris); 1997; 55(6):545-54. PubMed ID: 9499914
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia.
    Arafah M
    Turk Patoloji Derg; 2012; 28(1):38-43. PubMed ID: 22207430
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells.
    Shimizu H; Seiki T; Asada M; Yoshimatsu K; Koyama N
    Oncogene; 2003 Feb; 22(6):831-9. PubMed ID: 12584562
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bifunctional effect of resveratrol on the expression of ErbB2 in human breast cancer cell.
    Choi HK; Yang JW; Kang KW
    Cancer Lett; 2006 Oct; 242(2):198-206. PubMed ID: 16488535
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
    Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
    Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The immunohistochemically "ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative" subgroup is not a surrogate for the normal-like subtype in breast cancer.
    Yu KD; Shen ZZ; Shao ZM
    Breast Cancer Res Treat; 2009 Dec; 118(3):661-3. PubMed ID: 19714461
    [No Abstract]   [Full Text] [Related]  

  • 52. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
    Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
    Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Co-incidental increase in gene copy number of ERBB2 and LRIG1 in breast cancer.
    Ljuslinder I; Golovleva I; Henriksson R; Grankvist K; Malmer B; Hedman H
    Breast Cancer Res; 2009; 11(3):403. PubMed ID: 19490591
    [No Abstract]   [Full Text] [Related]  

  • 54. An unmet need: tailoring extended adjuvant endocrine therapy.
    Bianchini G; Gianni L
    Br J Cancer; 2013 Dec; 109(12):2951-3. PubMed ID: 24253504
    [No Abstract]   [Full Text] [Related]  

  • 55. Her2 and estrogen activate Src and inactivate p27 in breast cancer.
    Cancer Biol Ther; 2007 Feb; 6(2):138. PubMed ID: 17585413
    [No Abstract]   [Full Text] [Related]  

  • 56. Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.
    Harigopal M; Barlow WE; Tedeschi G; Porter PL; Yeh IT; Haskell C; Livingston R; Hortobagyi GN; Sledge G; Shapiro C; Ingle JN; Rimm DL; Hayes DF
    Am J Pathol; 2010 Apr; 176(4):1639-47. PubMed ID: 20150438
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantitative measures of oestrogen receptor and ERBB2 expression.
    Hayes DF
    Lancet Oncol; 2007 Mar; 8(3):184-5. PubMed ID: 17329185
    [No Abstract]   [Full Text] [Related]  

  • 58. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.
    Newman SP; Bates NP; Vernimmen D; Parker MG; Hurst HC
    Oncogene; 2000 Jan; 19(4):490-7. PubMed ID: 10698518
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer.
    Dressman MA; Baras A; Malinowski R; Alvis LB; Kwon I; Walz TM; Polymeropoulos MH
    Cancer Res; 2003 May; 63(9):2194-9. PubMed ID: 12727839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.